The stock of Adaptive Biotechnologies Corp (ADPT) has gone down by -6.48% for the week, with a -15.91% drop in the past month and a 13.72% rise in the past quarter. The volatility ratio for the week is 9.77%, and the volatility levels for the past 30 days are 9.34% for ADPT. The simple moving average for the past 20 days is -10.61% for ADPT’s stock, with a 28.30% simple moving average for the past 200 days.
Is It Worth Investing in Adaptive Biotechnologies Corp (NASDAQ: ADPT) Right Now?
Company’s 36-month beta value is 1.73.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ADPT is 141.70M, and currently, short sellers hold a 6.11% ratio of that floaft. The average trading volume of ADPT on March 18, 2025 was 1.60M shares.
ADPT) stock’s latest price update
The stock price of Adaptive Biotechnologies Corp (NASDAQ: ADPT) has plunged by -7.10 when compared to previous closing price of 7.54, but the company has seen a -6.48% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-11 that Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity.
Analysts’ Opinion of ADPT
Many brokerage firms have already submitted their reports for ADPT stocks, with JP Morgan repeating the rating for ADPT by listing it as a “Overweight.” The predicted price for ADPT in the upcoming period, according to JP Morgan is $15 based on the research report published on July 05, 2023 of the previous year 2023.
Scotiabank, on the other hand, stated in their research note that they expect to see ADPT reach a price target of $15. The rating they have provided for ADPT stocks is “Sector Outperform” according to the report published on January 05th, 2023.
Piper Sandler gave a rating of “Overweight” to ADPT, setting the target price at $14 in the report published on December 21st of the previous year.
ADPT Trading at -8.38% from the 50-Day Moving Average
After a stumble in the market that brought ADPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.73% of loss for the given period.
Volatility was left at 9.34%, however, over the last 30 days, the volatility rate increased by 9.77%, as shares sank -13.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.02% upper at present.
During the last 5 trading sessions, ADPT fell by -4.94%, which changed the moving average for the period of 200-days by +98.88% in comparison to the 20-day moving average, which settled at $7.84. In addition, Adaptive Biotechnologies Corp saw 16.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADPT starting from GRIFFIN MICHELLE RENEE, who sale 36,291 shares at the price of $7.19 back on Mar 13 ’25. After this action, GRIFFIN MICHELLE RENEE now owns 15,394 shares of Adaptive Biotechnologies Corp, valued at $260,932 using the latest closing price.
GRIFFIN MICHELLE RENEE, the Director of Adaptive Biotechnologies Corp, proposed sale 36,291 shares at $7.19 during a trade that took place back on Mar 13 ’25, which means that GRIFFIN MICHELLE RENEE is holding shares at $260,861 based on the most recent closing price.
Stock Fundamentals for ADPT
Current profitability levels for the company are sitting at:
- -0.86 for the present operating margin
- 0.58 for the gross margin
The net margin for Adaptive Biotechnologies Corp stands at -0.89. The total capital return value is set at -0.35. Equity return is now at value -62.41, with -26.57 for asset returns.
Based on Adaptive Biotechnologies Corp (ADPT), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -1.07. The debt to equity ratio resting at 0.44. The interest coverage ratio of the stock is -13.36.
Currently, EBITDA for the company is -128.76 million with net debt to EBITDA at -0.32. When we switch over and look at the enterprise to sales, we see a ratio of 6.02. The receivables turnover for the company is 4.29for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.89.
Conclusion
In a nutshell, Adaptive Biotechnologies Corp (ADPT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
